Since oncogenic HRAS contributes to tumor progression and is associated with the risk of recurrence [8], and RAS oncoproteins have been recognized as an undruggable cancer target [10], our results warrant further investigation as they suggest the potential of pterostilbene to overcome the resistance to cisplatin in bladder cancer with oncogenic HRAS and may fulfill an unmet clinical need. Here, HRAS is linked to urinary bladder cancer.